Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CORZ · Nasdaq · United States · Finance Services
In shortCore Scientific, Inc./tx is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it. Bank or insurer: tests that do not apply to them are left out.
| Operating marginShare of each sale left after running the business, before interest and tax. | -77.0% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -90.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | – | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -141.3% | n/a |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | n/a |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 364.0% | 0/100 |
| Operating margin volatility | 143.6% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -20.7% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 544 | 640 | 502 | 511 | 319 |
| Cost of revenue | 306 | 632 | 379 | 390 | 281 |
| Gross profit | 239 | 8.4 | 123 | 121 | 38 |
| Research & development | 7.7 | 27 | 7.2 | 12 | – |
| Selling, general & admin | – | – | 108 | 114 | 159 |
| Operating income | 131 | (2,110) | 9 | (142) | (246) |
| Pre-tax income | 63 | (2,163) | (246) | (1,437) | (288) |
| Income tax | 16 | (17) | 0.7 | 0.9 | 0.6 |
| Net income | 47 | (2,146) | (246) | (1,438) | (289) |
| Diluted EPS | $0.20 | −$6.30 | −$0.65 | −$4.87 | −$0.88 |
| Diluted shares (millions) | 233 | 341 | 380 | 256 | 318 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
Not computed: the model does not apply to banks and insurers.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 28, 2026